----item----
version: 1
id: {3E3DDD91-40A9-4919-85ED-4DC585E5E89C}
database: master
path: /sitecore/content/Pharma/MedtechInsight/Home/Articles/1995/07/24/BioLon generates almost $2 million in 1994 sales
parent: {B4F495B9-4F9B-4431-A2E1-D6E37812D302}
name: BioLon generates almost $2 million in 1994 sales
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----field----
field: {A4F985D9-98B3-4B52-AAAF-4344F6E747C6}
name: __Workflow
key: __workflow
content-length: 38

{926E6200-EB76-4AD4-8614-691D002573AC}
----version----
language: en
version: 1
revision: 115c7890-e510-4a98-b4d5-68e0b98a67ca

----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 718

<p>Sales of Bio-Technology General's visco-elastic hyaluronic acid product, BioLon, were $1.9 million in 1994, accounting for 17% of total product sales. BioLon was launched in France (by Laboratoires Chauvin as Biovisc), India and Mexico last year, bringing to eight the number of markets where it is available. Approvals are pending in several countries including the UK and Germany. In 1994, Bio-Technology reported total sales of $17.4 million, up 26% on the previous year and a net loss of $7.4 million ($22.8 million in 1993). Merck Frosst Canada has licensed a genetically engineered peptide from the Bio-Technology subsidiary, Bio-Cardia, for development as a thrombus imaging agent (Clinica No 620, p 20).</p>
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 49

BioLon generates almost $2 million in 1994 sales:
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 718

<p>Sales of Bio-Technology General's visco-elastic hyaluronic acid product, BioLon, were $1.9 million in 1994, accounting for 17% of total product sales. BioLon was launched in France (by Laboratoires Chauvin as Biovisc), India and Mexico last year, bringing to eight the number of markets where it is available. Approvals are pending in several countries including the UK and Germany. In 1994, Bio-Technology reported total sales of $17.4 million, up 26% on the previous year and a net loss of $7.4 million ($22.8 million in 1993). Merck Frosst Canada has licensed a genetically engineered peptide from the Bio-Technology subsidiary, Bio-Cardia, for development as a thrombus imaging agent (Clinica No 620, p 20).</p>
----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 233

{DC0A2BBF-AFE1-4257-A6DA-FF8AF24165B5}|{D96D1CF9-9C1A-4F0C-8A5A-E8349BE8C5F6}|{F5161CC2-772F-472E-A21C-BF196343462E}|{FC1DA89F-D8A0-415D-99B6-86FF397EC709}|{2360F67B-A7D7-4E2A-9C6C-5618FAE5CB5D}|{2EDCC1FF-26E4-4C6E-AF73-0F43F0F033B8}
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 48

BioLon generates almost $2 million in 1994 sales
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

19950724T000000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

19950724T000000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

19950724T000000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

MT053445
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 49

BioLon generates almost $2 million in 1994 sales:
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{FF38DC83-07D4-43F0-8C55-84EB64FAF35A}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

255254
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160622T184512Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

115c7890-e510-4a98-b4d5-68e0b98a67ca
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160622T184512Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
----field----
field: {3E431DE1-525E-47A3-B6B0-1CCBEC3A8C98}
name: __Workflow state
key: __workflow state
content-length: 38

{962542F5-554E-4DE8-BE4C-B0796FDAC854}
